Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Legend Biotech

- PMLiVE

Roche’s subcutaneous Ocrevus granted EC approval to treat relapsing and primary MS

The injection has the same twice-yearly schedule as the previously approved intravenous infusion

- PMLiVE

Takeda’s Fruzaqla approved by EC to treat metastatic colorectal cancer in adults

Approximately 538,000 new cases of colorectal cancer were diagnosed in Europe in 2022

- PMLiVE

Sobi receives EC marketing authorisation for Altuvoct in haemophilia A

The rare bleeding disorder affects approximately one in every 5,000 male births annually

- PMLiVE

J&J’s subcutaneous Tremfya shows promise in phase 3 Crohn’s disease study

Inflammatory bowel disease affects approximately four million people in Europe

- PMLiVE

AstraZeneca’s Truqap plus Faslodex granted EC approval to treat advanced breast cancer

More than 550,000 new cases of breast cancer were diagnosed in Europe in 2022

- PMLiVE

Johnson & Johnson’s investigational nipocalimab shows promise in Sjögren’s disease

The chronic autoimmune disease is estimated to affect four million people worldwide

- PMLiVE

J&J agrees $700m settlement with US states to resolve talcum powder claims

The company has ended global sales of the affected products in favour of cornstarch versions

EU flag

EMA announces launch of two advice pilots to improve clinical trials in Europe

The pilots are part of the Accelerating Clinical Trials in the EU initiative to foster high-quality clinical research

- PMLiVE

Roche’s ALK inhibitor Alecensa granted EC approval to treat early-stage lung cancer

Non-small cell lung cancer represents up to 85% of all lung cancer diagnoses

Biogen Idec building

Biogen’s Qalsody granted EC approval to treat rare form of ALS in adults

Mutations in the SOD1 gene are responsible for an estimated 2% of all ALS cases

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for adults with urothelial carcinoma

UC accounts for approximately 90% of all bladder cancers, the ninth most common cancer globally

- PMLiVE

J&J to acquire Numab’s Yellow Jersey Therapeutics in deal worth $1.25bn

The company will expand its immunology portfolio by gaining global rights to YJT’s NM26 in atopic dermatitis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links